These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16216515)

  • 1. Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
    Hu Y; Xiang JS; DiGrandi MJ; Du X; Ipek M; Laakso LM; Li J; Li W; Rush TS; Schmid J; Skotnicki JS; Tam S; Thomason JR; Wang Q; Levin JI
    Bioorg Med Chem; 2005 Dec; 13(24):6629-44. PubMed ID: 16216515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of potent and selective MMP-13 inhibitors.
    Wu J; Rush TS; Hotchandani R; Du X; Geck M; Collins E; Xu ZB; Skotnicki J; Levin JI; Lovering FE
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4105-9. PubMed ID: 16005220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and SAR of highly selective MMP-13 inhibitors.
    Li J; Rush TS; Li W; DeVincentis D; Du X; Hu Y; Thomason JR; Xiang JS; Skotnicki JS; Tam S; Cunningham KM; Chockalingam PS; Morris EA; Levin JI
    Bioorg Med Chem Lett; 2005 Nov; 15(22):4961-6. PubMed ID: 16153831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
    Baragi VM; Becher G; Bendele AM; Biesinger R; Bluhm H; Boer J; Deng H; Dodd R; Essers M; Feuerstein T; Gallagher BM; Gege C; Hochgürtel M; Hofmann M; Jaworski A; Jin L; Kiely A; Korniski B; Kroth H; Nix D; Nolte B; Piecha D; Powers TS; Richter F; Schneider M; Steeneck C; Sucholeiki I; Taveras A; Timmermann A; Van Veldhuizen J; Weik J; Wu X; Xia B
    Arthritis Rheum; 2009 Jul; 60(7):2008-18. PubMed ID: 19565489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).
    Kim SH; Pudzianowski AT; Leavitt KJ; Barbosa J; McDonnell PA; Metzler WJ; Rankin BM; Liu R; Vaccaro W; Pitts W
    Bioorg Med Chem Lett; 2005 Feb; 15(4):1101-6. PubMed ID: 15686921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
    Schnute ME; O'Brien PM; Nahra J; Morris M; Howard Roark W; Hanau CE; Ruminski PG; Scholten JA; Fletcher TR; Hamper BC; Carroll JN; Patt WC; Shieh HS; Collins B; Pavlovsky AG; Palmquist KE; Aston KW; Hitchcock J; Rogers MD; McDonald J; Johnson AR; Munie GE; Wittwer AJ; Man CF; Settle SL; Nemirovskiy O; Vickery LE; Agawal A; Dyer RD; Sunyer T
    Bioorg Med Chem Lett; 2010 Jan; 20(2):576-80. PubMed ID: 20005097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors.
    Xiang JS; Hu Y; Rush TS; Thomason JR; Ipek M; Sum PE; Abrous L; Sabatini JJ; Georgiadis K; Reifenberg E; Majumdar M; Morris EA; Tam S
    Bioorg Med Chem Lett; 2006 Jan; 16(2):311-6. PubMed ID: 16275085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.
    Noe MC; Natarajan V; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Otterness I; Bliven MA; Carty TJ; Barberia JT; Sweeney FJ; Liras JL; Vaughn M
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3385-8. PubMed ID: 15953722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.
    Monovich LG; Tommasi RA; Fujimoto RA; Blancuzzi V; Clark K; Cornell WD; Doti R; Doughty J; Fang J; Farley D; Fitt J; Ganu V; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Parker DT; Melton R; O'Byrne E; Pastor G; Pellas T; Quadros E; Reel N; Roland DM; Sakane Y; Singh H; Skiles J; Somers J; Toscano K; Wigg A; Zhou S; Zhu L; Shieh WC; Xue S; McQuire LW
    J Med Chem; 2009 Jun; 52(11):3523-38. PubMed ID: 19422229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.
    Kolodziej SA; Hockerman SL; Boehm TL; Carroll JN; DeCrescenzo GA; McDonald JJ; Mischke DA; Munie GE; Fletcher TR; Rico JG; Stehle NW; Swearingen C; Becker DP
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3557-60. PubMed ID: 20529684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sultam hydroxamates as novel matrix metalloproteinase inhibitors.
    Cherney RJ; Mo R; Meyer DT; Hardman KD; Liu RQ; Covington MB; Qian M; Wasserman ZR; Christ DD; Trzaskos JM; Newton RC; Decicco CP
    J Med Chem; 2004 Jun; 47(12):2981-3. PubMed ID: 15163180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of novel metalloproteinase inhibitors.
    Nakatani S; Ikura M; Yamamoto S; Nishita Y; Itadani S; Habashita H; Sugiura T; Ogawa K; Ohno H; Takahashi K; Nakai H; Toda M
    Bioorg Med Chem; 2006 Aug; 14(15):5402-22. PubMed ID: 16621578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.
    Blagg JA; Noe MC; Wolf-Gouveia LA; Reiter LA; Laird ER; Chang SP; Danley DE; Downs JT; Elliott NC; Eskra JD; Griffiths RJ; Hardink JR; Haugeto AI; Jones CS; Liras JL; Lopresti-Morrow LL; Mitchell PG; Pandit J; Robinson RP; Subramanyam C; Vaughn-Bowser ML; Yocum SA
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1807-10. PubMed ID: 15780611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo.
    Lewis EJ; Bishop J; Bottomley KM; Bradshaw D; Brewster M; Broadhurst MJ; Brown PA; Budd JM; Elliott L; Greenham AK; Johnson WH; Nixon JS; Rose F; Sutton B; Wilson K
    Br J Pharmacol; 1997 Jun; 121(3):540-6. PubMed ID: 9179398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel, potent, selective, and orally bioavailable human betaII-tryptase inhibitors.
    Sperandio D; Tai VW; Lohman J; Hirschbein B; Mendonca R; Lee CS; Spencer JR; Janc J; Nguyen M; Beltman J; Sprengeler P; Scheerens H; Lin T; Liu L; Gadre A; Kellogg A; Green MJ; McGrath ME
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4085-9. PubMed ID: 16725321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
    Li JJ; Nahra J; Johnson AR; Bunker A; O'Brien P; Yue WS; Ortwine DF; Man CF; Baragi V; Kilgore K; Dyer RD; Han HK
    J Med Chem; 2008 Feb; 51(4):835-41. PubMed ID: 18251495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.
    Levin JI; Chen JM; Du MT; Nelson FC; Wehr T; DiJoseph JF; Killar LM; Skala S; Sung A; Sharr MA; Roth CE; Jin G; Cowling R; Di L; Sherman M; Xu ZB; March CJ; Mohler KM; Black RA; Skotnicki JS
    Bioorg Med Chem Lett; 2001 Nov; 11(22):2975-8. PubMed ID: 11677139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453.
    Kohno T; Hochigai H; Yamashita E; Tsukihara T; Kanaoka M
    Biochem Biophys Res Commun; 2006 May; 344(1):315-22. PubMed ID: 16603129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.
    Becker DP; DeCrescenzo G; Freskos J; Getman DP; Hockerman SL; Li M; Mehta P; Munie GE; Swearingen C
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2723-5. PubMed ID: 11591510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.
    Ruminski PG; Massa M; Strohbach J; Hanau CE; Schmidt M; Scholten JA; Fletcher TR; Hamper BC; Carroll JN; Shieh HS; Caspers N; Collins B; Grapperhaus M; Palmquist KE; Collins J; Baldus JE; Hitchcock J; Kleine HP; Rogers MD; McDonald J; Munie GE; Messing DM; Portolan S; Whiteley LO; Sunyer T; Schnute ME
    J Med Chem; 2016 Jan; 59(1):313-27. PubMed ID: 26653735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.